15.30

2.00% 0.30

Myriad Genetics Inc (MYGN)

Overview News Price History Option Chain Financials Why MYGN Down? Discussions Forecast Stock Split

Myriad Genetics Inc stock is traded at $15.30, with a volume of 661.07K. It is up +2.00% in the last 24 hours and down -34.59% over the past month. Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Previous Close:

$15.00

Open:

$14.93

24h Volume:

661.07K

Relative Volume:

0.88

Market Cap:

$1.36B

Revenue:

$802.20M

Net Income/Loss:

$-155.20M

P/E Ratio:

-4.5536

EPS:

-3.36

Net Cash Flow:

$-141.30M

1W Performance:

-3.04%

1M Performance:

-34.59%

6M Performance:

-38.82%

1Y Performance:

-15.28%

1-Day Range:

$14.72

$15.33

1-Week Range:

$14.72

$16.07

52-Week Range:

$14.72

$29.30

Myriad Genetics Inc Stock (MYGN) Company Profile

Name

Myriad Genetics Inc

Sector

Healthcare (1193)

Industry

Diagnostics & Research (57)

Phone

801-584-3600

Address

322 NORTH 2200 WEST, SALT LAKE CITY, UT

Employee

2,700

Twitter

@myriadgenetics

Next Earnings Date

2024-11-07

Latest SEC Filings

MYGN's Discussions on Twitter

Compare MYGN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MYGN	15.30	1.36B	802.20M	-155.20M	-141.30M	-3.36
TMO	512.84	195.55B	42.37B	6.14B	7.78B	15.26
DHR	233.10	166.92B	23.74B	3.89B	4.98B	7.93
A	128.57	36.94B	6.50B	1.41B	1.42B	3.82
IQV	194.38	35.03B	15.32B	1.41B	1.96B	5.95
IDXX	418.61	33.80B	3.84B	866.24M	792.60M	9.80

Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-21-23	Resumed	Piper Sandler	Neutral
Dec-19-23	Initiated	Wells Fargo	Equal Weight
Dec-14-23	Initiated	Guggenheim	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Jul-05-23	Resumed	JP Morgan	Underweight
May-23-23	Upgrade	Goldman	Sell → Buy
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform
Oct-06-22	Initiated	Stephens	Equal-Weight
Oct-15-21	Resumed	Cowen	Market Perform
Jun-15-21	Initiated	Raymond James	Mkt Perform
Jun-03-21	Initiated	Goldman	Sell
Sep-26-19	Downgrade	BofA/Merrill	Neutral → Underperform
Aug-14-19	Downgrade	Piper Jaffray	Overweight → Neutral
Aug-02-19	Upgrade	BofA/Merrill	Underperform → Neutral
Aug-01-19	Upgrade	Barclays	Underweight → Equal Weight
Jul-29-19	Downgrade	Needham	Strong Buy → Hold
Jul-09-19	Downgrade	Cowen	Outperform → Market Perform
Mar-12-19	Reiterated	Needham	Strong Buy
Jan-03-19	Initiated	Needham	Strong Buy
Nov-30-18	Upgrade	Goldman	Sell → Neutral
Oct-10-18	Upgrade	Piper Jaffray	Neutral → Overweight
Jul-11-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-21-18	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jan-29-18	Initiated	Goldman	Sell
Jan-22-18	Reiterated	Barclays	Equal Weight
Jan-05-18	Initiated	BTIG Research	Buy
Oct-02-17	Resumed	Leerink Partners	Mkt Perform
Aug-09-17	Reiterated	Barclays	Equal Weight
Feb-08-17	Upgrade	Ladenburg Thalmann	Sell → Neutral
Jan-18-17	Initiated	Deutsche Bank	Sell
Oct-10-16	Downgrade	Ladenburg Thalmann	Neutral → Sell

View All

Myriad Genetics Inc Stock (MYGN) Latest News

Nov 20, 2024

Myriad Genetics Announces Incorporation of its Proprietary - GlobeNewswire

Nov 20, 2024

Myriad Genetics Expands Illumina Partnership, Integrates Key Cancer Testing Technology | MYGN Stock News - StockTitan

Nov 20, 2024

MYGN Stock Might Gain From SneakPeek Availability in Retail Stores - MSN

Nov 20, 2024

Myriad Genetics (NASDAQ:MYGN) Downgraded to "Hold" Rating by StockNews.com - MarketBeat

Nov 20, 2024

Breast Cancer Screening and Diagnostic Techniques Market - openPR

Nov 20, 2024

Nov 19, 2024

Myriad Genetics (NASDAQ:MYGN) Reaches New 1-Year Low After Analyst Downgrade - MarketBeat

Nov 19, 2024

Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy - GlobeNewswire

Nov 19, 2024

Myriad Genetics Launches Industry's First 8-Week Prenatal DNA Screen | MYGN Stock News - StockTitan

Nov 19, 2024

Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley - Yahoo Finance

Nov 19, 2024

SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer - GlobeNewswire Inc.

Nov 19, 2024

Nov 18, 2024

Morgan Stanley Has Lowered Expectations for Myriad Genetics (NASDAQ:MYGN) Stock Price - MarketBeat

Nov 18, 2024

State of New Jersey Common Pension Fund D Acquires New Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat

Nov 18, 2024

Nov 17, 2024

MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC - GlobeNewswire

Nov 17, 2024

Nov 15, 2024

Simplify Asset Management Inc. Buys Shares of 173,626 Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat

Nov 15, 2024

Nov 14, 2024

Predictive Genetic Testing & Consumer/Wellness Genomics - GlobeNewswire

Nov 14, 2024

Nov 13, 2024

Long Term Trading Analysis for (MYGN) - Stock Traders Daily

Nov 13, 2024

Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch - The Manila Times

Nov 13, 2024

Minimal Residual Disease Testing Market Share, Growth Drivers, - openPR

Nov 13, 2024

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price - Simply Wall St

Nov 13, 2024

Myriad Genetics stock hits 52-week low at $16.6 amid market shifts - Investing.com Australia

Nov 13, 2024

Nov 12, 2024